Benzinga's Top Pre-Market NASDAQ Gainers (SVNT, CYPB, UTSI, NOVL)

Savient Pharmaceuticals Inc SVNT rose 27.37% to $18.80 in the pre-market session. FDA has approved SVNT's gout drug for adults who were not getting any results from the conventional therapy. Cypress Bioscience Inc CYPB added 13.39% to $3.98 in the pre-market session. Ramius Value and Opportunity Advisors LLC initiated an offer to buy all the outstanding shares of CYPB at $4.25 per share. UTStarcom Inc UTSI moved up 7.25% to $2.07 in the pre-market session. UTSI has won the bid for the Equipment Purchase Project of Jinan Radio & TV Network Center, thereby becoming the exclusive broadband solution provider of the Center. Novell Inc NOVL soared 5.03% to $5.85 in the pre-market trading. NOVL's trailing-twelve-month gross margin is 78.54%. Read more from Benzinga's Company news. Click here to get trading ideas that could bring you a 100% return.